CECD: Clinical Endocannabinoid Deficiency
In this article we will talk about clinical endocannabinoid deficiency, simply known as CECD. It is a disorder associated with multiple diseases and conditions such as esophageal spasms, migraine, fibromyalgia, and also irritable bowel syndrome.
It is worth mentioning that this term was coined by Dr. Ethan Russo only 17 years ago, so today it is still considered a theory. For Ethan Russo there are many brain disorders that have their origin in a deficiency of neurotransmitters. Even, that many other conditions can occur due to a deficiency in endocannabinoids.
What is clinical endocannabinoid deficiency (CECD)?
Research on CECD published by Russo himself in 2016 shows that endocannabinoid deficiency is linked to suffering from fibromyalgia, migraines, and irritable bowel syndrome.
Marijuana deficiencies, as it is also known, is based on the theory that diseases are the result of problems that are generated in the endocannabinoid system. This could occur due to a shortage in the production of endocannabinoids in our body.
It is also possible that it is due to the absence of or abnormalities in your receptors. In other words, when our body is not able to maintain in balance the physiological systems, all these diseases arise, including
. The interesting thing about this is that to date, all of these diseases seem to be related to the immune system.
Diseases resulting from endocannabinoid deficiency
As mentioned, clinical endocannabinoid deficiency CECD, leads to a number of diseases and conditions. According to Dr. Russo, this deficiency may be the underlying cause of the following disorders.
This is a disease that affects different areas of our brain as well as multiple neurochemicals. To date, it is not known precisely what causes migraine, although it is known that genetic predisposition seems to be a determining factor in its development.
Dr. Russo’s research on this subject reveals that anandamide is related to the production of serotonin, as well as the modulation of pain. The findings point to high serotonin levels contributing to the onset of migraines.
Therefore, migraines could be counteracted with a higher concentration of anandamide. According to Dr. Russo’s theory, a deficiency in the production of anandamide could cause the onset of migraines as a consequence of a lack of serotonin regulation.
In this case it is a chronic disorder that causes chronic pain to the sufferer. Today there is no cure for fibromyalgia, so only through traditional medicine has it been possible to alleviate the symptoms. Dr. Russo’s studies indicate that the endocannabinoid system has the ability to regulate nociceptive thresholds.
Nociceptors are responsible for detecting pain and at the same time, transmitting signals to the brain so that this information can be processed. In the absence of this regulation, diseases that generate chronic pain appear. And just as with migraines, serotonin may also play a role in fibromyalgia.
So far, research has revealed that cannabinoids have the potential to block spinal, peripheral, and gastrointestinal mechanisms that promote the onset of pain.
Irritable bowel syndrome
It is also one of the diseases that can have its origin in clinical endocannabinoid deficiency CECD. Research reveals that the role of cannabinoids in the development of irritable bowel syndrome is similar to what happens with migraine and fibromyalgia.
In other words, serotonin seems to play a very important role, especially since people with irritable bowel syndrome have high levels of serotonin in their blood. However, it is important to note that this is not true for all types of irritable bowel syndrome.
The role of serotonin
As has been described in each of these diseases,the theory indicates that serotonin is a determining factor in the emergence of these conditions. Consequently, through the control or manipulation of serotonin levels, it is possible to develop treatments for each disease.
In this sense, cannabinoids would be a fundamental part of each of the treatments. This is due to the influence that cannabinoids have on certain endocannabinoids, such as anandamide.
This means that clinical endocannabinoid deficiency CECD could be effectively treated with cannabinoid drugs. However, it is important to clarify that more studies are needed to better understand how endocannabinoid deficiency affects our bodies.
Can CBD combat clinical endocannabinoid deficiency?
It is true that marijuana deficiencies are based on scientific studies, in none of these investigations is mentioned precisely how it could be treated. In fact, the exact role that cannabinoids play is still not entirely clear. The theory suggests that the production of anandamide appears to be crucial in combating the diseases that are related to CECD.
As for CBD, studies have shown that it can inhibit the enzyme FAAH, known as fatty acid amide hydrolase. This enzyme contributes to the breakdown of anandamide, and prevents it from remaining in the body for a long time.
What is interesting is that if the mechanisms or triggers could be identified, CBD could very possibly be used to treat the aforementioned diseases. It is even known that CBD can also directly affect certain serotonin receptors within the brain.
The characteristics of each disease most likely indicate a relationship between migraine, fibromyalgia, and irritable bowel syndrome. Dr. Russo’s studies indicate a potential complication with certain neurotransmitters that are linked to the endocannabinoid system.
If the existence of clinical endocannabinoid deficiency CECD is proven, it would be possible to develop targeted treatments, and not just settle for research that for the moment are only theories.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Subscribe to our newsletter
Subscribe and receive a 10% discount on your purchase.